www.pathology-associates.com
Phone: (559) 326-2800
Fax: (559) 326-2822

PATHOLOGY ASSOCIATES
William C. Pitts, MD., Medical Director
305 Park Creek Drive
Clovis, CA 93611

Name:	**Pathology, Miss Testy**		**Case No.:** **P12-21917**
Patient No.:	**PA999999**	Facility:	**Office**
Birthdate:	**3/10/1990** Age: **22** Sex **F**	Other MRN:	**99999**
Pt. Phone:	**(559) 326-2800**	Encounter No.:	
Doctor:	**San Joaquin Valley, M.D.**	Date of Surgery:	**9/4/2012**
Copies To:	**Pathology University - Fresno**	Date Received:	**9/4/2012**

GYN CYTOLOGY CONSULTATION

SPECIMEN SOURCE: Cervical
SPECIMEN TYPE: Focal Point and HPV
CLINICAL HISTORY: Routine Pap; LMP: 8/5/12; Previous Pap: 2009; GC/CT Vial

SMEAR ADEQUACY:
Satisfactory smear for interpretation with endocervical component present.

INTERPRETATION RESULTS:

EPITHELIAL CELL ABNORMALITY: SQUAMOUS INTRAEPITHELIAL LESION, HIGH GRADE (INCLUDING CIN II, CIN III, and/or CIS).

GONORRHEA/CHLAMYDIA RESULTS
GONORRHEA RESULTS: *******POSITIVE*******
CHLAMYDIA RESULTS: *******POSITIVE*******

HPV HIGH RISK RESULTS:
High Risk HPV type 16: Negative
High Risk HPV type 18: **********POSITIVE**********
Other High-Risk HPV types: Negative
Other High-Risk HPV types include: 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68.

Interpretation performed by Paul H. Atmajian MD, FCAP. Electronically signed 9/11/2012 2:23 PM

***SAMPLE PAP*:**
Correlated to Surgical Case (S12-52436)

1: V76.2

DISCLAIMERS:

SurePath/FocalPoint/GS: This processed specimen slide was analyzed using the FDA approved BD FocalPoint® Slide Profiler/GS and/or manual review.

HPV: The Cobas® HPV test from Roche Diagnostics utilizes Real-Time PCR technology to simultaneously detect HPV 16, HPV 18, and a pool of 12 other High-Risk HPV genotypes(31,33,35,39,45,51,52,56,58,59,66, and 68) for use with ThinPrep and SurePath patient specimens. This test does not detect DNA of HPV Low-Risk genotypes. A HPV result of negative does not exclude levels which are undetectable or below the pre-set threshold.

GC/CT: The GC/CT test is preformed on the GEN-PROBE instrument utilizing the Aptima Combo 2 Assay. This methodology has been approved by the Food and Drug Administration (FDA).

AFFIRM: Direct DNA probe test. This assay has been approved by the Food and Drug Administration (FDA).

**The PAP test (cervical-vaginal cytology smear) is a screening test with recognizable but low probabilities of a false negative and false positive results. These results should be used in conjunction with your patient's prior and current clinical history and physical findings.